Roche’s sales rebound like test COVID-19 help power growth

A photo showing the logo of The Swiss pharmaceutical giant Roche in Basel.


by Roche first-half net profit increased 2% to 8.22 billion Swiss francs (8.96 billion dollars) and sales increased 8% at constant exchange rates to 30.71 billion francs better than expected as the Swiss drug manufacturer benefited from demand for Covid-19 test.

He kept his full-year forecast for sales grow in single-digit low to media rate at constant exchange rates, with nucleus earnings for share it grows more or less like sales.

“Roche expects to increase the dividend in Swiss francs further “, it added. Diagnostics division sales grew by 51% in the first half because of the high demand for Covid-19 test and strong momentum in test routinely, Roche said, helping to compensate for a 3% decline in sales of pharmaceuticals, although sales of pharmaceuticals have increased in the second quarter after a faint start to the year.

“We reached good results in the first half, mainly thanks to the demand for our new drugs e test COVID-19. The Pharma Division has started to grow again in the second quarter. Basic diagnostics business shows strong momentum. As expected, demand for THE test for Covid-19 have peaked in the second quarter”said managing director Severin Schwan.

Read More About Business News around the World here!


Leave a Reply